GlassScriptPhysician profile
Brandon Keith Van Deman
NPI 1629693841
$1,266.02
in general payments reported to CMS, 2019-2025
17 companies · $450 in 2025
The $450 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $51.42 · 2023: $272 · 2024: $493 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,214.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $238.17 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $223.50 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $156.20 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $152.61 | 2023-2024 | |
| Exact Sciences Corporation | $96.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $71.36 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $47.98 | 2024-2025 | Airsupra, Breztri |
| Irhythm Technologies, INC. | $43.96 | 2022-2024 | Zio Monitor, Zio Xt Patch |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.65 | 2025 | Jardiance |
| Amgen INC. | $41.66 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Mylan Specialty L.P. | $35.46 | 2024 | Yupelri |
| Optinose US, INC. | $22.68 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $20.90 | 2025 | Zoryve |
| Lundbeck LLC | $20.31 | 2025 | Rexulti |
| Dynavax Technologies Corporation | $18.06 | 2025 | Heplisav-B |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $16.77 | 2025 | Voquezna |
| Tolmar, INC. | $16.39 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Van Deman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.